Two Sigma Advisers
DFTX

Two Sigma Advisers’s Definium Therapeutics DFTX Stock Holding History

Two Sigma Advisers’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-65,281
Closed -$874K – 1307
2025
Q4 		$874K Sell
65,281
-16,202
-20% -$201K ﹤0.01% 1555
2025
Q3 		$961K Buy
+81,483
New +$760K ﹤0.01% 1481
2025
Q1 		– Sell
-24,650
Closed -$172K – 2510
2024
Q4 		$172K Buy
24,650
+5,400
+28% +$37.2K ﹤0.01% 2148
2024
Q3 		$110K Sell
19,250
-65,767
-77% -$457K ﹤0.01% 2157
2024
Q2 		$613K Buy
85,017
+63,100
+288% +$552K ﹤0.01% 1796
2024
Q1 		$206K Buy
+21,917
New +$125K ﹤0.01% 2205
2022
Q3 		– Sell
-1,100
Closed -$11K – 2669
2022
Q2 		$11K Sell
1,100
-2,367
-68% -$29.9K ﹤0.01% 2583
2022
Q1 		$58K Sell
3,467
-293
-8% -$5.08K ﹤0.01% 2569
2021
Q4 		$78K Buy
+3,760
New +$120K ﹤0.01% 2437
2021
Q3 		– Sell
-2,900
Closed -$150K – 2591
2021
Q2 		$150K Buy
+2,900
New +$152K ﹤0.01% 2308

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Two Sigma Advisers's DFTX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Definium Therapeutics (DFTX) in Q1 2026, closing a stake of 65,281 shares — an estimated $874K sold.

Two Sigma Advisers first reported a position in DFTX in Q2 2021 and held it in 10 quarters. The position peaked at $961K in Q3 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Two Sigma Advisers reported no remaining Definium Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 65,281 Definium Therapeutics shares in Q1 2026, an estimated $874K.
  • Two Sigma Advisers first reported a position in Definium Therapeutics in Q2 2021 and held it in 10 quarters.
  • Two Sigma Advisers's Definium Therapeutics position peaked at $961K in Q3 2025.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.